References
- Reinhard T, Larkin F. Corneal disease. Recent developments in diagnosis and therapy. Berlin/Heidelberg: Springer Verlag; 2013
- Elsahn AF, Yildiz EH, Jungkind DL, et al. In vitro susceptibility patterns of methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus corneal isolates to antibiotics. Cornea 2010;29:1131–1135
- An MM, Shen H, Zhang JD, et al. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2013;41:426–433
- Sueke H, Kaye S, Neal T, et al. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest Ophthalmol Vis Sci 2010;51:2519–2524
- Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011;66:iv7–iv15
- Duke SL, Kump LI, Yuan Y, et al. The safety of intraocular linezolid in rabbits. Invest Ophthalmol Vis Sci 2010;51:3115–3119
- Saleh M, Jehl F, Dory A, et al. Ocular penetration of topically applied linezolid in a rabbit model. J Cataract Refract Surg 2010;36:488–492
- Saleh M, Lefèvre S, Acar N, et al. Efficacy of intravitreal administrations of linezolid in an experimental model of S. aureus-related endophthalmitis. Invest Ophthalmol Vis Sci 2012;53:4832–4841
- Tu EY, Jain S. Topical linezolid 0.2% for the treatment of vancomycin-resistant or vancomycin-intolerant gram-positive bacterial keratitis. Am J Ophthalmol 2013;155:1095–1098 .e1
- American Academy of Ophthalmology Cornea/External Disease panel. Preferred Practice Pattern® Guidelines: bacterial keratitis. San Francisco, CA: American Academy of Ophthalmology; 2013
- Hedayatfar A, Hashemi H, Asgari S, Chee SP. Comparison of efficacy and ocular surface toxicity of topical preservative-free methylprednisolone and preserved prednisolone in the treatment of acute anterior uveitis. Cornea 2014;33:366–372
- Versura P, Profazio V, Campos EC. One month use of Systane improves ocular surface parameters in subjects with moderate symptoms of ocular dryness. Clin Ophthalmol 2008;2:629–635
- Ong SJ, Huang YC, Tan HY, et al. Staphylococcus aureus keratitis: a review of hospital cases. PLoS One 2013;8:e80119
- Dolz-Marco R, Udaondo P, Gallego-Pinazo R, et al. Topical linezolid for refractory bilateral Mycobacterium chelonae post-laser-assisted in situ keratomileusis keratitis. Arch Ophthalmol 2012;130:1475–1476
- Dowson DG, Ubels JL, Edelhauser HF. Cornea and sclera. In: Levin LA, Nilsson SFE, Ver Hoeve J, Wu SM, eds. Adler’s physiology of the eye. 11th ed. Edinburgh, New York: Saunders/Elsevier; 2011:71--130
- Ioannidou M, Apostolidou-Kiouti F, Haidich AB, et al. Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis. Eur J Pediatr 2014;173:1179–1186
- Tas T, Kucukbayrak A, Hakyemez IN, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus keratitis in rabbits. Cornea 2013;32:1052–1057
- Ekdawi NS, Fiscella R, Schreckenberger P, Tu E. Topical linezolid in streptococcus pneumoniae corneal ulcer model in rabbits. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 4910
- Chédru-Legros V, Fines-Guyon M, Chérel A, et al. Fortified antibiotic (vancomycin, amikacin and ceftazidime) eye drop stability assessment at −20 degrees C. J Fr Ophtalmol 2007;30:807–813
- Curtin J, Cormican M, Fleming G, et al. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother 2003;47:3145–3148